Allander Biotechnologies is starting its first-in-patient clinical trial for its first-in-class topical therapeutic to treat oral mucositis in 2026.  Although not life-threatening, Oral mucositis is often the primary side effect compromising the effective treatment of cancer impacting 400,000 patients annually in the US.  The worldwide oral mucositis market was estimated at nearly $1.85B in 2024 and is projected to reach nearly $3.72B by 2034, a CAGR of 7.2%.

Allander received a $2.4M NIH grant to fund the clinical trial, and has raised an additional $3M through a convertible debt note. We have previously raised two rounds of seed funding for a total of $2M, and have received $9M in non-dilutive grant funding.  We are interested in raising an additional $2M in funding to support our GLP dermal toxicity studies in pigs to support our planned clinical trial in atopic dermatitis, radiation dermatitis and other inflammatory skin indications.